Condition: Hematologic Disorder · Bleeding Disorder · Connective Tissue Disorder · Sponsor: American Thrombosis and Hemostasis Network
In parallel with the growth of ATHN's clinical studies, the number of new therapies for all blood disorders is increasing significantly. Some of the recently FDA-approved therapies for congenital and acquired hematologic conditions have not yet demonstrated long-term safety and effectiveness beyond the pivotal trials that led to their approval. In addition, results from well controlled, pivotal studies often cannot be replicated once a therapy has been approved for general use.2,3,4,5 In 2019 alone, the FDA has issued approvals for 24 new therapies for congenital and acquired hematologic conditions.6 In addition, almost 10,000 new studies for hematologic diseases are currently registered on www.clinicaltrials.gov.7 With this increase in potential new therapies possible, it is imperative that clinicians and clinical researchers in the field of non-neoplastic hematology have a uniform, secure, unbiased, and enduring method to collect long-term safety and efficacy data. As emphasized in a recently published review, accurate, uniform and quality national data collection is critical in clinical research, particularly for longitudinal cohort studies covering a lifetime of biologic risk.8
This description comes directly from the study's public registry record.
Carol Fedor, ND, RN, CCRC · 800-360-2846 · cfedor@athn.org
Nana Ama Afari-Dwamena, MPH · 800-360-2846 · nafaridwamena@athn.org
Always discuss trial participation with your own doctor first.
| Arizona Hemophilia and Thrombosis Treatment Center at Phoenix Children's Hospital | Phoenix, Arizona, United States | Recruiting |
| Arkansas Center for Bleeding Disorders | Little Rock, Arkansas, United States | Recruiting |
| Orthopaedic Institute for Children HTC | Los Angeles, California, United States | Recruiting |
| Childrens Hospital Los Angeles | Los Angeles, California, United States | Recruiting |
| UCSF Benioff Children's Hospital Oakland | Oakland, California, United States | Recruiting |
| University of California at Davis Hemophilia Treatment Center | Sacramento, California, United States | Recruiting |
| Loma Linda Hemoglobinopathy and Inherited Bleeding Disorder Program | San Bernardino, California, United States | Recruiting |
| Hemophilia & Thrombosis Treatment Center at UC San Diego Health | San Diego, California, United States | Recruiting |
| Rady Children's Hospital San Diego | San Diego, California, United States | Recruiting |
| University of California, San Francisco Hemophilia & Thrombosis Center | San Francisco, California, United States | Recruiting |
| Connecticut Children's Medical Center | Hartford, Connecticut, United States | Recruiting |
| Yale Hemophilia Treatment Center | New Haven, Connecticut, United States | Recruiting |
+ 59 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04398628